Resof Total Tablet

Resof Total Tablet is a premium direct-acting antiviral (DAA) medication developed for the treatment of chronic Hepatitis C Virus (HCV) infection, particularly for patients who require retreatment after previous antiviral therapy has not achieved the desired outcome. This advanced fixed-dose combination contains Sofosbuvir 400 mg, Velpatasvir 100 mg, and Voxilaprevir 100 mg, three powerful antiviral agents that work together to eliminate the Hepatitis C virus by targeting multiple stages of its life cycle. Resof Total Tablet is recognized worldwide for its exceptional effectiveness, broad genotype coverage, and high sustained virologic response (SVR) rates, making it one of the most reliable treatment options for complex Hepatitis C cases.

The triple-action formula combines three clinically proven antiviral medicines with complementary mechanisms of action. Sofosbuvir is an NS5B RNA polymerase inhibitor that blocks the replication of viral RNA, preventing the Hepatitis C virus from producing new viral particles. Velpatasvir is an NS5A inhibitor that interferes with viral replication and assembly, while Voxilaprevir is an NS3/4A protease inhibitor that prevents the virus from processing proteins necessary for its survival and multiplication. Together, these three antiviral agents provide comprehensive suppression of the Hepatitis C virus, reducing the likelihood of drug resistance and significantly improving treatment success.

One of the major advantages of Resof Total Tablet is its pan-genotypic activity, making it effective against all six major Hepatitis C genotypes (Genotypes 1, 2, 3, 4, 5, and 6). It is particularly beneficial for patients who have previously been treated with direct-acting antiviral medications but did not achieve complete viral clearance. Healthcare professionals may also prescribe this therapy for certain patients with compensated liver disease after careful clinical evaluation. The standard treatment duration is generally 12 weeks, although the exact course should always be determined by a qualified healthcare provider based on the patient's medical history, liver condition, and previous treatment experience.

Clinical research has demonstrated that Resof Total Tablet delivers sustained virologic response (SVR) rates exceeding 95%, even among many patients who have failed previous antiviral regimens. Achieving SVR means the Hepatitis C virus becomes undetectable after treatment, which is considered a functional cure. Successful treatment significantly reduces the risk of progressive liver damage, fibrosis, cirrhosis, liver failure, and hepatocellular carcinoma while improving long-term liver function and overall quality of life.

Resof Total Tablet is administered as one tablet taken orally once daily with food, or exactly as prescribed by a healthcare professional. Taking the medication with food helps optimize absorption and therapeutic effectiveness. Patients should take the tablet at the same time each day and complete the entire prescribed treatment course without missing doses. Interrupting treatment or discontinuing therapy prematurely may reduce its effectiveness and increase the risk of viral persistence or relapse.

Compared with older Hepatitis C treatment regimens, Resof Total offers a convenient oral dosing schedule and is generally well tolerated. Some patients may experience mild side effects such as headache, fatigue, nausea, diarrhea, abdominal discomfort, or mild weakness. These symptoms are typically temporary and manageable throughout the treatment period. Serious side effects are uncommon when the medication is taken under proper medical supervision. Regular laboratory monitoring may be recommended to evaluate liver function, assess viral response, and ensure safe treatment progression.

Before starting Resof Total Tablet, patients should inform their healthcare provider about any history of liver disease, kidney impairment, hepatitis B infection, HIV infection, pregnancy, breastfeeding, or any other significant medical conditions. They should also disclose all prescription medications, over-the-counter medicines, vitamins, and herbal supplements they are currently taking, as certain drugs may interact with Sofosbuvir, Velpatasvir, or Voxilaprevir. Alcohol consumption should be avoided during treatment because it may worsen liver damage and interfere with the body's recovery process.

Resof Total Tablets should be stored in their original packaging at room temperature in a cool, dry place away from direct sunlight, excessive heat, and moisture. The medication should remain out of reach of children and should not be used beyond the expiration date printed on the packaging. Proper storage helps preserve the medicine's stability, potency, and therapeutic effectiveness throughout its shelf life.

At Ayurmed Medicose, we are committed to supplying authentic, high-quality antiviral medicines that meet stringent international pharmaceutical standards. We provide genuine Resof Total Tablets sourced from trusted manufacturers, ensuring reliable quality, secure packaging, competitive pricing, and prompt worldwide delivery. Our dedication to product authenticity, ethical pharmaceutical distribution, and customer satisfaction has established Ayurmed Medicose as a trusted partner for hospitals, pharmacies, healthcare professionals, wholesalers, and international buyers. By delivering dependable Hepatitis C treatment solutions with consistent quality and professional service, we continue to support improved patient care and better healthcare outcomes across global markets.